Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
22.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$-3.7
EPS
$--
Face value
--
Shares outstanding
1,472,890
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
60 Degrees Pharmaceuticals, Inc. (SXTP)
| -65.7 | -7.5 | 18.8 | -89.0 | -- | -- | -- |
|
BSE Sensex*
| 4.5 | -0.9 | 10.8 | 6.2 | 15.9 | 19.7 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
|---|---|
|
60 Degrees Pharmaceuticals, Inc. (SXTP)
| -89.3 |
|
S&P Small-Cap 600
| 7.0 |
|
BSE Sensex
| 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
60 Degrees Pharmaceuticals, Inc. (SXTP)
|
2.2 | 3.3 | 0.7 | -10.3 | -1,278.2 | -203.6 | -- | 0.0 |
| 0.3 | 4.9 | 7.5 | -3,074.4 | -146,429.4 | -139.2 | 0 | 1.1 | |
| 0.7 | 162.9 | 1.0 | -155.9 | -15,251.5 | -- | -- | 0.0 | |
| 120.9 | 12,188.4 | 5,512.6 | 494.7 | 17.0 | 16.3 | 24.9 | 5.6 | |
| 1.1 | 200.2 | 0.0 | -3.3 | -- | -- | -- | 0.0 | |
| 8.2 | 218.0 | 7.0 | -20.0 | -271.4 | -13.4 | -- | 1.5 | |
| 2.3 | 21.9 | 2.9 | -8.4 | -181.0 | -- | -- | 86.2 | |
| 1.5 | 191.7 | 41.6 | -202.0 | -496.2 | -136.3 | -- | 1.8 | |
| 0.5 | 17.0 | 0.0 | -1.0 | -- | -12.4 | 5.8 | 1.8 | |
| 0.9 | 3.4 | 0.0 | -1.0 | -- | -40.9 | -- | 1.2 |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria... preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia. Read more
Chairman, CEO & President
Dr. Geoffrey Stuart Dow
Chairman, CEO & President
Dr. Geoffrey Stuart Dow
Headquarters
Washington, DC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of 60 Degrees Pharmaceuticals, Inc (SXTP) stood at $ 8 Mln as on 31-Mar-25
The share price of 60 Degrees Pharmaceuticals, Inc (SXTP) is $2.21 (NASDAQ) as of 13-Jun-2025 16:00 EDT. 60 Degrees Pharmaceuticals, Inc (SXTP) has given a return of -89.02% in the last 1 years.
60 Degrees Pharmaceuticals, Inc (SXTP) has a market capitalisation of $ 3 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of 60 Degrees Pharmaceuticals, Inc (SXTP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 60 Degrees Pharmaceuticals, Inc (SXTP) and enter the required number of quantities and click on buy to purchase the shares of 60 Degrees Pharmaceuticals, Inc (SXTP).
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
The CEO & director of Dr. Geoffrey Stuart Dow. is 60 Degrees Pharmaceuticals, Inc (SXTP), and CFO & Sr. VP is Dr. Geoffrey Stuart Dow.
There is no promoter pledging in 60 Degrees Pharmaceuticals, Inc (SXTP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
20
|
|
|
19
|
|
|
2
|
|
|
2
|
|
|
1
|
|
|
0
|
|
|
0
|
|
|
1,204
|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | Ratios |
|---|---|
|
Return on equity(%)
|
-203.55
|
|
Operating margin(%)
|
-1278.16
|
|
Net Margin(%)
|
-1564.58
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of 60 Degrees Pharmaceuticals, Inc (SXTP) was $0 Mln.
$-0.07
(
